Project Grant R01AI183604

Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $3.3M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to examine the role of B cell-dependent regulatory T cells in maintaining B cell tolerance and preventing autoimmunity. The $807,799 award to the University of Chicago aims to identify B cell-dependent regulatory T cell clones, define their developmental requirements and functions, and determine the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,018,216 to the University of Chicago to conduct research on the contributions of BRWD1-mediated cohesin conversion to B cell biology. The research aims to define BRWD1 functions in germinal centers, determine the mechanisms and importance of BRWD1-mediated GAGA motif recognition, and understand how BRWD1 and cohesin...
This Project Grant award of $1,083,816.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of Colorado-Denver to investigate the role of CD79A as a molecular switch regulating B cell activation and tolerance. The key objectives are to determine how individual CD79A immunoreceptor tyrosine-based activation motif (ITAM) tyrosines impact B cell receptor (BCR) signaling and downstream...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $441,202 to The Regents of the University of California, Berkeley to conduct research on the role of ex-Tregs (ex-regulatory T cells) in autoimmunity and cancer immunity. The goal is to investigate whether ex-Tregs, which arise from regulatory T cells (Tregs), are required to promote anti-cancer immunity and...
This federal Project Grant award for $246,623.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at New York University School of Medicine to study the molecular control of tolerogenic dendritic cell function. The research aims to characterize the dendritic cell subset responsible for maintaining T cell tolerance, including investigating aberrant cytokine...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 Allergy and Infectious Diseases Research, is funding a $556,843 research initiative at the University of Pittsburgh to investigate the development and regulation of the extrafollicular B cell response. The key objectives are to: Examine the role of B cells in enhancing the extrafollicular response and test the self-renewal capacity of the extrafollicular B cell population....
This Project Grant award, totaling $441,098.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The grant aims to investigate the antagonistic relationship between the transcription factors IRF4 and BACH2 in regulating germinal center B cell fates and promoting lymphomagenesis. The research project, with a performance period from July 2025 to June 2027, will use transgenic...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine how germinal center (GC) responses are controlled in health and how governance loss promotes immune deficiencies and autoimmune diseases. The key objectives are to establish the lineage and functional differences between induced T follicular regulatory (iTFR) and natural TFR (nTFR) cells, and assess...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,428,212 to St. Jude Children's Research Hospital Inc. from July 2025 through June 2029 to conduct research on the "Epigenetic Checkpoint Regulation of Naive T-Cell Quiescence and Peripheral Tolerance". The research aims to understand how intrinsic checkpoint regulators, specifically the ascorbate-TET axis, maintain naive T-cell...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $657,673 to the Regents of the University of Minnesota to conduct research on non-deletional CD8+ T cell tolerance. The research aims to define the gene regulation that inhibits self-reactive CD8+ T cells and classify different types of self-reactive CD8+ T cell clones, in order to understand which tolerance...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $3,288,215 to The University of Texas MD Anderson Cancer Center to conduct research on the role of the GRAIL gene in B cell tolerance and B cell-mediated inflammation. The key objectives are to:

  1. Determine the molecular mechanisms by which GRAIL regulates B cell tolerance and activation. This will involve identifying the specific targets and functions of GRAIL in controlling B cell responses.

  2. Assess the role of GRAIL in antibody-dependent and -independent B cell functions, and evaluate its impact on immune-related adverse events in a model of immune checkpoint inhibitor-induced arthritis.

The research aims to provide new insights into the genetic and signaling control of B cell tolerance, which could lead to the development of new tools for early detection and treatment of B cell-mediated autoimmune diseases. The award has an initial term of 4 years, from August 1, 2025 to July 31, 2029.

Generated 8/5/25, 6:45 AM